Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non-Current Deffered Revenue (2016 - 2023)

Historic Non-Current Deffered Revenue for Arrowhead Pharmaceuticals (ARWR) over the last 9 years, with Q4 2025 value amounting to $53.8 million.

  • Arrowhead Pharmaceuticals' Non-Current Deffered Revenue changed N/A to $53.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $53.8 million, marking a year-over-year change of. This contributed to the annual value of $56.0 million for FY2022, which is 5745.09% down from last year.
  • Arrowhead Pharmaceuticals' Non-Current Deffered Revenue amounted to $53.8 million in Q4 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Non-Current Deffered Revenue ranged from a high of $131.5 million in Q3 2021 and a low of $1.1 million during Q1 2023
  • Its 4-year average for Non-Current Deffered Revenue is $75.2 million, with a median of $75.5 million in 2021.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Non-Current Deffered Revenue crashed by 1076.75% in 2022 and then tumbled by 9880.23% in 2023.
  • Quarter analysis of 4 years shows Arrowhead Pharmaceuticals' Non-Current Deffered Revenue stood at $106.5 million in 2021, then plummeted by 61.69% to $40.8 million in 2022, then plummeted by 97.36% to $1.1 million in 2023, then surged by 4906.98% to $53.8 million in 2025.
  • Its last three reported values are $53.8 million in Q4 2025, $1.1 million for Q1 2023, and $40.8 million during Q4 2022.